People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bright Uro, Inc. | — | Biotechnology | Series B | $46.0M | $70.6M | 2023 |
| Spinal Singularity, Inc. | — | Biotechnology | Seed | $4.9M | $88.6M | 2016 |
Derek Herrera at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Derek Herrera on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kurt Azarbarzin | 1 | 3 |
| Kenneth Baker | 1 | 3 |
| Christopher Jennings | 1 | 2 |
| Sherman Williams | 1 | 2 |
| Martha Aronson | 1 | 2 |
| Andrew Gilbert | 1 | 2 |
| Bill Colone | 1 | 2 |
| David Kaysen | 1 | 2 |
| Kevin Hershberger | 1 | 1 |
| Kevin Herschberger | 1 | 1 |
| Mike Frazzette | 1 | 1 |
| Michael Frazzette | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.